Zevra Therapeutics (NASDAQ:ZVRA) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Zevra Therapeutics (NASDAQ:ZVRA) in a research note published on Wednesday,Benzinga reports. The firm currently has a $20.00 price target on the stock. HC Wainwright also issued estimates for Zevra Therapeutics’ Q4 2024 earnings at ($0.36) EPS, FY2024 earnings at ($1.92) EPS, FY2025 earnings at ($0.23) EPS, FY2026 earnings at $0.77 EPS, FY2027 earnings at $1.86 EPS and FY2028 earnings at $2.51 EPS.

A number of other brokerages have also weighed in on ZVRA. Canaccord Genuity Group decreased their price objective on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. JMP Securities assumed coverage on shares of Zevra Therapeutics in a research note on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price target on the stock. Maxim Group upped their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. William Blair raised shares of Zevra Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Finally, Roth Mkm boosted their target price on Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Zevra Therapeutics currently has a consensus rating of “Buy” and an average target price of $21.00.

Zevra Therapeutics Stock Up 5.0 %

ZVRA stock opened at $9.59 on Wednesday. Zevra Therapeutics has a 52 week low of $4.20 and a 52 week high of $9.64. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The firm has a 50-day simple moving average of $8.19 and a 200-day simple moving average of $6.63. The stock has a market capitalization of $511.61 million, a P/E ratio of -4.87 and a beta of 1.93.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.25). The firm had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $5.04 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same quarter last year, the firm posted ($0.40) earnings per share. Equities analysts forecast that Zevra Therapeutics will post -1.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zevra Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sanctuary Advisors LLC acquired a new stake in shares of Zevra Therapeutics during the second quarter valued at about $474,000. Jacobs Levy Equity Management Inc. increased its holdings in Zevra Therapeutics by 102.4% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock valued at $201,000 after purchasing an additional 17,557 shares during the last quarter. Simplify Asset Management Inc. purchased a new stake in Zevra Therapeutics in the third quarter valued at approximately $833,000. Price T Rowe Associates Inc. MD acquired a new position in Zevra Therapeutics during the first quarter worth $64,000. Finally, Vanguard Group Inc. boosted its position in shares of Zevra Therapeutics by 3.6% during the first quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock worth $9,883,000 after buying an additional 58,866 shares during the period. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.